Narkolepsi

01Pathophysiology

Narcolepsy is fundamentally a disorder of sleep-wake state boundary control, not simply "being too sleepy." The core problem in Type 1 narcolepsy is the selective, autoimmune-mediated destruction of hypocretin (orexin)-producing neurons located in the lateral hypothalamus. Hypocretin is a neuropeptide that stabilizes the boundaries between wakefulness, NREM sleep, and REM sleep. When these neurons are destroyed (typically greater than 90% loss), the brain loses its ability to maintain stable wakefulness and to properly gate REM sleep. This is why patients experience intrusions of REM sleep phenomena into wakefulness.

Cataplexy is the sudden, transient loss of voluntary muscle tone triggered by strong positive emotions (laughter, surprise, excitement). This occurs because REM sleep atonia, normally confined to REM sleep, intrudes into waking consciousness. The emotional limbic circuits that normally activate during wakefulness now inappropriately trigger the pontomedullary REM-atonia pathways. This is why cataplexy is so closely linked to emotion and why it is pathognomonic for narcolepsy Type 1. Consciousness is fully preserved during an episode, which distinguishes it from syncope or seizure.

Sleep paralysis represents another REM intrusion: the patient is cognitively awake but the skeletal muscle atonia of REM sleep persists, rendering them unable to move for seconds to minutes during sleep-wake transitions. Hypnagogic hallucinations (at sleep onset) and hypnopompic hallucinations (upon awakening) are the dream-imagery component of REM sleep breaking through into wakefulness. These are often vivid, multi-sensory, and can be terrifying, frequently involving a sense of a threatening presence in the room.

The genetic susceptibility is linked to the HLA-DQB1*06:02 allele, present in over 98% of Type 1 narcolepsy patients (compared to roughly 25% of the general population). This HLA association strongly supports an autoimmune etiology. Environmental triggers such as streptococcal pharyngitis, H1N1 influenza infection, and the AS03-adjuvanted H1N1 vaccine (Pandemrix) have been implicated as initiating events through molecular mimicry.

In Type 2 narcolepsy, hypocretin levels are normal. The pathophysiology remains poorly understood, but the clinical phenotype includes excessive daytime sleepiness and MSLT abnormalities without cataplexy. Some experts hypothesize partial hypocretin neuron loss insufficient to reduce CSF levels below the diagnostic threshold.

02Classification and Clinical Manifestation

Excessive daytime sleepiness (EDS) is the most disabling and universally present symptom. Patients describe an irresistible urge to sleep, often in socially inappropriate situations (during meals, conversations, examinations). A hallmark feature is that brief naps (10 to 20 minutes) are refreshing, which contrasts with idiopathic hypersomnia where naps are prolonged and unrefreshing. Vignettes will often describe a student or worker who "falls asleep during a meeting and wakes up feeling refreshed."

Cataplexy ranges from subtle (jaw sagging, head drooping, speech slurring, knee buckling) to dramatic (full postural collapse). The trigger is almost always a positive emotion: laughter is the most common. Importantly, consciousness is preserved throughout the episode, episodes last seconds to a couple of minutes, and there is no postictal confusion. This distinguishes cataplexy from seizures and syncope.

Automatic behaviors are another underrecognized feature: patients may continue routine tasks (writing, driving, talking) during microsleep episodes with amnesia for the event.

03Diagnostic Workup

The diagnostic approach to narcolepsy has a deliberate sequence that exam writers love to test.

Step 1: Clinical suspicion. The presentation of a young patient with irresistible daytime sleepiness, especially when accompanied by cataplexy, should immediately raise the suspicion. A thorough sleep history is the first move, including sleep duration, schedule, nap behavior, medication use, and substance intake.

Step 2: Exclude insufficient sleep and other sleep disorders. Before any specialized testing, you must confirm that the patient is not simply sleep-deprived. A sleep diary or actigraphy for 1 to 2 weeks is required. The patient should maintain a regular sleep schedule with at least 7 hours of sleep per night before undergoing the MSLT. Medications that suppress REM sleep (SSRIs, SNRIs, TCAs, stimulants) must be tapered and discontinued at least 2 weeks prior, as they artificially reduce SOREMPs and cause false-negative results.

Step 3: Overnight PSG. This is performed the night before the MSLT. Its primary role is to exclude obstructive sleep apnea and other causes of sleep disruption that could mimic narcolepsy. The PSG itself may show a shortened REM latency (less than 15 minutes, termed a "SOREMP"), which if present, counts as one of the $\ge 2\backslash geq\; 2$ required SOREMPs on the following day's MSLT.

Step 4: MSLT (Best Initial Test for confirmation). This is the cornerstone diagnostic study. Performed the day after PSG, the patient is given 4 to 5 nap opportunities at 2-hour intervals. Two findings are required: a mean sleep latency $\le 8\backslash leq\; 8$ minutes (indicating the pathological speed of sleep onset) AND $\ge 2\backslash geq\; 2$ SOREMPs (indicating the inappropriate intrusion of REM sleep into nap periods). Normal individuals do not enter REM sleep during 20-minute nap opportunities.

Step 5: CSF Hypocretin-1 (Most Accurate Test for Type 1). A lumbar puncture measuring CSF hypocretin-1 $\le 110\text{ pg/mL}\backslash leq\; 110\backslash \; \backslash text\{pg/mL\}$ is the gold standard for diagnosing Type 1 narcolepsy. This test is considered when the MSLT is equivocal, when patients cannot discontinue REM-suppressing medications, or when clinical certainty is needed. It has a sensitivity of approximately 87% and a specificity greater than 99% for Type 1 narcolepsy. This test is not useful for Type 2, where levels are normal.

HLA typing is supportive but never diagnostic in isolation due to its poor positive predictive value (the allele is common in the general population). It is primarily useful for its negative predictive value: if HLA-DQB1*06:02 is absent, Type 1 narcolepsy is extremely unlikely.

04Management and Treatment

Non-pharmacological measures (foundation for all patients):
Structured lifestyle modifications are always the first step and remain an adjunct to medications. Scheduled short naps (15 to 20 minutes, once or twice daily) are uniquely effective in narcolepsy because these naps are genuinely refreshing (unlike in other hypersomnias). Patients should maintain a consistent sleep-wake schedule, avoid alcohol and heavy meals, and receive counseling on driving safety and occupational hazards.

Pharmacological management of excessive daytime sleepiness:
Modafinil is the most widely accepted first-line agent for EDS. It is a wake-promoting agent whose mechanism is not fully understood but involves dopamine reuptake inhibition. It has a favorable side-effect profile compared to traditional stimulants. A critical exam point is that modafinil induces CYP3A4 and reduces the effectiveness of oral contraceptives, requiring patients to use alternative or additional contraception.

If modafinil is insufficient, solriamfetol (a dual dopamine/norepinephrine reuptake inhibitor) is a newer option with strong evidence. Pitolisant, a histamine H3 receptor inverse agonist, is another non-stimulant alternative approved for both EDS and cataplexy in some guidelines.

For refractory EDS, traditional psychostimulants (methylphenidate, amphetamine salts) remain effective but carry higher risks of cardiovascular side effects, tolerance, dependence, and abuse potential. They are second-line agents.

Pharmacological management of cataplexy:
Sodium oxybate (gamma-hydroxybutyrate/GHB) is the most effective treatment for cataplexy and is also the only agent that improves all five cardinal symptoms of narcolepsy (EDS, cataplexy, disrupted nocturnal sleep, sleep paralysis, and hallucinations). It is taken at bedtime and again 2.5 to 4 hours later (two nightly doses). The starting dose is 4.5 g/night, titrated every 1 to 2 weeks up to 9 g/night. It is a CNS depressant and a Schedule III controlled substance, requiring enrollment in a restricted distribution program (REMS). It must never be combined with alcohol or other CNS depressants.

REM-suppressing antidepressants (venlafaxine, fluoxetine, clomipramine) reduce cataplexy by suppressing REM sleep. They are less effective than sodium oxybate but are more accessible. A critical teaching point: abrupt discontinuation of these agents can trigger rebound cataplexy, sometimes presenting as continuous cataplectic episodes termed status cataplecticus, which can be dangerous and may mimic a neurological emergency.

Pregnancy considerations: Sodium oxybate, stimulants, and most antidepressants are generally avoided during pregnancy. Management typically shifts to non-pharmacological strategies and careful risk-benefit discussion.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get narcolepsy questions wrong is by failing to recognize cataplexy as the distinguishing feature of Type 1 narcolepsy. A vignette describing a young patient who collapses while laughing but remains fully conscious is not a seizure, not syncope, and not a psychiatric condition. The preservation of consciousness during the episode and the emotional trigger are the two features that clinch the diagnosis.

The second major trap involves diagnostic sequencing. Students frequently select CSF hypocretin-1 as the first test to order. While it is the most accurate test for Type 1, the correct initial workup is an overnight PSG followed by an MSLT. CSF hypocretin measurement is reserved for ambiguous presentations, inability to perform a valid MSLT, or when patients cannot safely discontinue REM-suppressing medications.

A third pitfall is the MSLT validity problem. Test writers may embed a vignette where a patient is taking an SSRI or SNRI (for depression, anxiety, or already for cataplexy) and then undergoes an MSLT that shows no SOREMPs. The student must recognize that REM-suppressing medications invalidate the MSLT and should be discontinued at least 2 weeks before testing. Without recognizing this, the student may incorrectly conclude the patient does not have narcolepsy.

Another frequently tested pearl: modafinil reduces the efficacy of oral contraceptives. Expect a question pairing a young woman newly started on modafinil with a question about counseling or contraceptive management.

Finally, students should remember that abrupt withdrawal of antidepressants used for cataplexy can precipitate status cataplecticus, a continuous state of cataplectic episodes. This is a "next best step" question in disguise: the answer is to resume the medication, not to order imaging or start anticonvulsants.

The core competency being tested across narcolepsy questions is the ability to connect the pathophysiology (hypocretin deficiency causing REM-wake boundary instability) to each clinical feature, to sequence the diagnostic workup correctly (PSG then MSLT, with CSF hypocretin as the definitive test), and to recognize the pharmacological nuances (modafinil drug interactions, sodium oxybate restrictions, antidepressant withdrawal risks).